Chemoprevention of breast cancer
โ Scribed by Trevor J. Powles; Janet R. Hardy; Susan E. Ashley; David Cosgrove; Jane B. Davey; Mitchell Dowsett; Alan McKinna; Anthony G. Nash; Susan K. Rundle; H. Dudley Sinnett; Colin R. Tillyer; Jennifer G. Treleaven
- Publisher
- Springer US
- Year
- 1989
- Tongue
- English
- Weight
- 641 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The activity of our group is focused on the conduction of chemoprevention clinical trials of breast cancer in at-risk subjects, among which we include women on hormone replacement therapy (HRT). The role of the insulin-like growth factor (IGF) system and of mammographic breast density as surrogate b
In human mammary carcinoma, positive immunohistochemical staining for p53 protein is not always indicative of mutation in the p53 gene. Although positive staining is seen in excess of 50% of tumours, mutations have been found in only some 20% of cases. In this presentation, positive p53 staining in
Despite years of intensive research, breast cancer remains a major cause of death among women. New strategies to combat breast cancer are being developed, one of the most exciting of which is the use of chemopreventive agents. Resveratrol (RES) is a polyphenolic compound found in plants that seems t